Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Sponsor: AbbVie
Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 125 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 55 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Official title: A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
125
Start Date
2025-10-29
Completion Date
2030-12
Last Updated
2026-03-11
Healthy Volunteers
No
Conditions
Interventions
Telisotuzumab Adizutecan
Intravenous (IV) Infusion
Locations (26)
City of Hope National Medical Center /ID# 275613
Duarte, California, United States
Valkyrie Clinical Trials /ID# 275547
Los Angeles, California, United States
Yale University School of Medicine /ID# 275978
New Haven, Connecticut, United States
Florida Cancer Specialists - North /ID# 277137
St. Petersburg, Florida, United States
Northwestern University Feinberg School of Medicine /ID# 276436
Chicago, Illinois, United States
University of Chicago Medical Center /ID# 275342
Chicago, Illinois, United States
START Midwest /ID# 276603
Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999
New York, New York, United States
Duke Cancer Institute /ID# 275604
Durham, North Carolina, United States
The University of Texas MD Anderson Cancer Center /ID# 275663
Houston, Texas, United States
South Texas Accelerated Research Therapeutics (START) /ID# 276608
San Antonio, Texas, United States
Start Mountain Region /ID# 276607
West Valley City, Utah, United States
The Chaim Sheba Medical Center /ID# 274342
Ramat Gan, Tel Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 274344
Tel Aviv, Tel Aviv, Israel
Hadassah Medical Center-Hebrew University /ID# 274343
Jerusalem, Israel
Rabin Medical Center. /ID# 274341
Petah Tikva, Israel
Nagoya University Hospital /ID# 276336
Nagoya, Aichi-ken, Japan
Kyushu University Hospital /ID# 276302
Fukuoka, Fukuoka, Japan
Hokkaido University Hospital /ID# 276333
Sapporo, Hokkaido, Japan
Kyoto University Hospital /ID# 276398
Kyoto, Kyoto, Japan
Tohoku University Hospital /ID# 276344
Sendai, Miyagi, Japan
Okayama University Hospital /ID# 276299
Okayama, Okayama-ken, Japan
National Cancer Center Hospital /ID# 276297
Chuo-Ku, Tokyo, Japan
Seoul National University Hospital /ID# 275703
Seoul, Seoul Teugbyeolsi, South Korea
Yonsei University Health System Severance Hospital /ID# 276184
Seoul, Seoul Teugbyeolsi, South Korea
Samsung Medical Center /ID# 275705
Seoul, Seoul Teugbyeolsi, South Korea